Geron Corporation Q3 2025 Earnings Recap

GERN Q3 2025 November 6, 2025

Geron Corporation reported third quarter 2025 revenues of $47.2 million, reflecting a 3% decline in net product sales for RYTELO, as the company emphasizes its commitment to increasing utilization and education around its therapy for lower-risk MDS.

Earnings Per Share Beat

$-0.03 vs $-0.04 est.

+18.2% surprise

Revenue Miss

47227000 vs 53340380 est.

-11.5% surprise

Market Reaction

1-Day -0.92%

5-Day +14.68%

30-Day +9.17%

Key Takeaways

New patient starts for RYTELO increased significantly to 36% from 30% in the previous quarter, despite an overall revenue decline.
The company expanded its prescribing accounts by 15%, adding approximately 150 new accounts, bringing the total to 1,150.
Geron is initiating a strategic focus on increasing awareness among healthcare providers and enhancing relationships with key opinion leaders as part of a comprehensive plan to drive sales growth.
New Chief Commercial Officer, Ahmed ElNawawi, joins to strengthen the execution of Geron’s commercial strategy and address the challenges in the current marketplace.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GERN on AllInvestView.